Boston musings.
P2B or P3 may be the burning question.
Pathways??
I wonder if the new HIV/225 patents will be part of a change of tack, with regard to the parameters of the next trial. Will they pursue eradication or will they pursue to prove the human value of the immune response over a longer period.
Is a treatment interruption trial, as mentioned previously by MM in an interview, no longer a pipedream here?
Will they take aim at both?
How?
The Boston CROI connection, page-18
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $45.11M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.8¢ | $13.69K | 278.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 268713 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 46070 | 1 |
View Market Depth
| Last trade - 15.37pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.0¢ |
Change
-0.002 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 4.9¢ | 5.0¢ | 4.9¢ | 61814 | ||
| Last updated 13.21pm 17/06/2024 ? | |||||
| BIT (ASX) Chart |
